Clin Surg | Volume 8, Issue 1 | Research Article | Open Access

Metastatic Tumors have Become the Most Important Entity in Parotid Gland Cancer

Franzen AM1,2*

1Department of Otorhinolaryngology, Head and Neck Surgery, Brandenburg Medical School, University Medical Centre Ruppin Brandenburg, Germany
2Joint Faculty of the University of Potsdam, Brandenburg University of Technology Cottbus-Senftenberg and Brandenburg Medical School, Germany

*Correspondance to: Franzen AM 

Fulltext PDF

Abstract

Aim: Lymphatic tissue enclosed in the parenchyma is the precondition for metastases to the parotid gland. Significance and clinical parameters of metastatic tumors are presented. Methods: The clinical data of 837 patients over a period of 40 years who received a parotidectomy for a tumor disease are analyzed. Two 20 years intervals are compared. Results: Of those, 144 tumors were malignant (17.2%) and 72 were metastases. The proportion of metastases was 24.4% in the first two decades and 61.6% in the second. Metastatic parotid tumor affected male patients in 75% with a mean age of 71.1 (23 and 93 years). At 81.8% metastatic tumors were squamous cell carcinoma. Metastatic tumors were in 51 cases cutaneous tumors of the head and neck, in 8 cases carcinoma of the oral cavity or pharynx and in 4 of the outer ear canals, in 6 cases the primary tumor was located below the clavicle and another 4 cases were diagnosed as CUP syndromes. Discussion: Metastatic tumors have become the most important entity in malignant parotid tumors of our patients. Indications of a metastatic disease are older age, male sex, actinically damaged skin, histological findings and tumor diseases, in particular skin carcinomas, in history. Conclusion: Distinguishing between glandular primary and parotid metastasis is an essential precondition for stratifying risk, planning treatment and aftercare in malignant parotid neoplasms.

Citation:

Franzen AM. Metastatic Tumors have Become the Most Important Entity in Parotid Gland Cancer. Clin Surg. 2023; 8: 3622..

Subscribe to Our Newsletter